Pasithea Therapeutics (KTTA) Enterprise Value (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Enterprise Value for 4 consecutive years, with -$9.4 million as the latest value for Q3 2024.
- Quarterly Enterprise Value rose 9.95% to -$9.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was -$9.4 million through Sep 2024, up 9.95% year-over-year, with the annual reading at -$16.3 million for FY2023, 50.64% up from the prior year.
- Enterprise Value hit -$9.4 million in Q3 2024 for Pasithea Therapeutics, down from -$7.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$7.1 million in Q2 2024 to a low of -$53.0 million in Q4 2021.
- Historically, Enterprise Value has averaged -$27.6 million across 4 years, with a median of -$26.8 million in 2023.
- Biggest five-year swings in Enterprise Value: plummeted 106.16% in 2022 and later soared 75.48% in 2023.
- Year by year, Enterprise Value stood at -$53.0 million in 2021, then soared by 37.53% to -$33.1 million in 2022, then soared by 50.64% to -$16.3 million in 2023, then surged by 42.68% to -$9.4 million in 2024.
- Business Quant data shows Enterprise Value for KTTA at -$9.4 million in Q3 2024, -$7.1 million in Q2 2024, and -$12.0 million in Q1 2024.